Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 in Chronic Cougher
Overview
This study is for therapeutic confirmation of AG1321001 to evaluate the safety and efficacy as an anti-tussive agent in cough patients.
Full Title of Study: “Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of AG1321001 Capsule as an Anti-Tussive Agent in Cough Patients: Double Blinded, Randomized, Placebo and Active Rug Comparative, Parallel Designed Phase III Study”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Masking: Triple (Participant, Care Provider, Investigator)
Interventions
- Drug: AG1321001(drug)
Clinical Trial Outcome Measures
Primary Measures
- Cough severity, Cough specific Quality of Life
Secondary Measures
- Daily cough symptom, Cough frequency
Participating in This Clinical Trial
Inclusion Criteria
1. Adult between the ages of 18 and 70. 2. Patient who has cough symptom caused by following diseases: chronic bronchitis, bronchiectasis, gastroesophageal reflux disease, postnasal drip syndrome caused by rhinitis, sinusitis, rhinopharyngitis, rhinolaryngitis. 3. Patient requiring internal treatment due to cough symptom, who has coughing more than 3 weeks. 4. patient who will continue to cough more than 1 week.(by physician's judgment) 5. Patient who decided to participate in this clinical trial at his(her) own will and agreed in written letter of consent. 6. Patient who is trustworthy, ready for cooperation and observing the restrictions during the trial period. Exclusion Criteria:
1. Patient who is accompanied by the seriously abnormal symptom in respiratory system, such as Acute infectious Pulmonary Disease, Tuberculosis. 2. Patient who has clinical history of sensitivity to Xanthine drug. 3. Patient who has Peptic Ulcer or Asthma (Except Cicatrix) 4. Patient whose liver or kidney function is seriously abnormal: Including the cases of sGOT, sGPT, bilirubin and blood creatinine value exceeding twice of their upper normal limit. 5. Patient whose heart function is abnormal: including the case of showing abnormal EKG test value that is clinically significant. 6. Patient who has experience to have participated in other clinical trial within two months before starting the trial. 7. Pregnant woman, lactating woman. 8. patient who has convulsion or alcoholism. 9. patient who take medicines which can not use combination with AG1321001.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 70 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
- Provider of Information About this Clinical Study
- Jung Hoon Han / Project Development Team,
- Overall Official(s)
- Young-hwan Kim, MD, PhD, Study Chair, Seoul National University Hospital, Seoul, 110-744, Korea, Republic of
- Choon-Taek Lee, MD, PhD, Principal Investigator, Seoul National University Bundang Hospital, Sungnam, Korea, Republic of
- Hee-Soon Chung, MD, PhD, Principal Investigator, Seoul National University Boramae Hospital, Seoul, 156-707, Korea, Republic of
- Ki-suk Jung, MD, PhD, Principal Investigator, Hallym University Sacred Heart Hospital, Anyang, Kyunggi, 430-070, Korea, Republic of
- Joon Chang, MD, PhD, Principal Investigator, Severance Hospital, Seoul, 120-752, Korea, Republic of
- Chul-min Ahn, MD, PhD, Principal Investigator, Yongdong Sevenrance Hospital, Seoul, 135-720, Korea, Republic of
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.